BDBM359537 4-{(6R or S)-1-({2- chloro-6-[1- (trifluoromethyl)cyclo- propyl]phenyl}car- bonyl)-6-[(3- methoxyazetidin-1- yl)carbonyl]-4,5,6,7- tetrahydro-1H- indazol-3-yl}-2- methylbenzoic acid::US10221142, Example 21C

SMILES COC1CN(C1)C(=O)C1CCc2c(C1)n(nc2-c1ccc(C(O)=O)c(C)c1)C(=O)c1c(Cl)cccc1C1(CC1)C(F)(F)F

InChI Key InChIKey=VHHNYHCMJZABAS-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 359537   

TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359537(4-{(6R or S)-1-({2- chloro-6-[1- (trifluoromethyl)...)
Affinity DataIC50:  1.20nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent